Dow Surges Over 100 Points; Pfizer Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Benzinga
Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 100 points, while Pfizer reported better-than-expected earnings and raised its FY 2025 EPS guidance.
Sector Movements: Consumer discretionary shares increased by 0.7%, but energy stocks fell by 0.4%. Notable stock movements included significant gains for SolarMax Technology and Y-mAbs Therapeutics, while Agilon Health saw a drastic decline of 57%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.920
Low
24.00
Averages
28.56
High
35.00
Current: 25.920
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Dividends Drive Returns for Pfizer and JNJ Investments
- Dividend Growth: Johnson & Johnson (JNJ) has raised its quarterly dividend to $1.34 for the 64th consecutive time, resulting in an annual payout of $2,680, reflecting its AAA-rated financial stability and $19.7 billion in free cash flow, which bolsters investor confidence.
- Revenue Performance: JNJ's Innovative Medicine segment generated $15.426 billion in Q1 2026, an 11.2% year-over-year increase, primarily driven by strong sales of products like DARZALEX, further solidifying its market position.
- Pfizer's Dividend Strategy: Pfizer (PFE) offers a 6.8% dividend yield, and despite facing post-COVID sales declines, management prioritizes dividend payments and has stated no share buybacks are anticipated in 2026, ensuring stable returns for shareholders.
- Portfolio Income: The combined investment of 500 shares in these two companies generates $3,540 in annual passive income, with a blended yield of 2.79%, showcasing the appeal and flexibility of dividend stocks amid market fluctuations.
See More
Is It Possible to Retire on $500,000?
- Investment Return Requirements: To achieve a median U.S. household income of $88,510 from an initial investment of $500,000, an annual return of 17.7% is necessary, which is challenging but feasible with strategic investments.
- Social Security Impact: Including the average annual Social Security benefit of $26,148 reduces the required annual return to 12.5%, and for married couples receiving benefits, it drops to 7.2%, highlighting the critical role of Social Security in retirement planning.
- Ares Capital Advantages: As the largest publicly traded business development company, Ares Capital boasts a diversified portfolio worth $21.5 billion and offers a high dividend yield of 10.6%, having maintained stable or increasing dividends for 67 consecutive quarters, demonstrating strong profitability and resilience.
- Energy Transition Potential: Energy Transfer LP operates over 140,000 miles of pipelines, providing an attractive distribution yield of approximately 7.2%, with management projecting annual distribution growth of 3% to 5%, positioning the company strongly for growth amid energy transition trends.
See More
Ares Capital and Pfizer Offer High-Yield Stocks for Retirement
- Stable Dividends from Ares Capital: Ares Capital (NASDAQ: ARCC), the largest publicly traded business development company, offers a high dividend yield of 10.6% and has maintained stable or increasing dividends for 67 consecutive quarters, demonstrating resilience and profitability even during economic crises.
- Tailwinds from Energy Transition: Energy Transfer (NYSE: ET), a leading midstream energy company in North America with over 140,000 miles of pipelines, expects to increase its distribution by 3% to 5% annually and benefits from the rapid build-out of AI data centers, enhancing its market position.
- Pfizer's Long-Term Commitment: Pfizer (NYSE: PFE) boasts a forward dividend yield of 6.8% and has increased its dividend for 16 consecutive years; despite facing patent expirations, the company is investing in new product development and acquisitions to bolster revenue growth potential, expecting solid growth beyond 2028.
- Retirement Investment Advice: While Ares Capital, Energy Transfer, and Pfizer present good investment options for retirement, relying solely on these three stocks is unwise; investors are advised to create a diversified portfolio to mitigate risks and enhance return potential.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales growth of 56%, highlighting its strong performance in the weight-loss market.
- Dividend Yield Comparison: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at only 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, posing challenges in attracting income-focused investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, placing it at a competitive disadvantage.
- Future Outlook: Although Pfizer faces multiple challenges, it is actively developing new drugs and plans to conduct 20 major studies in 2026, demonstrating its ongoing efforts in drug development and potential for recovery.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Eli Lilly Sales Surge: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving a remarkable 56% overall sales growth, highlighting its strong position in the weight-loss market.
- Pfizer's Dividend Appeal: Pfizer offers a dividend yield of 6.6%, significantly higher than Eli Lilly's 0.6%, making it more attractive to income-focused investors despite facing challenges such as patent expirations.
- Challenges for Pfizer: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, raising concerns about its future growth.
- R&D Outlook: Despite short-term challenges, Pfizer is conducting 20 major studies on new drug candidates, indicating ongoing investment in drug development, which may enable it to regain growth momentum in the future.
See More
Eli Lilly vs Pfizer: Dividend Yield Comparison
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales gain of 56% for the company, highlighting its strong performance in the weight-loss market.
- Dividend Yield Discrepancy: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at a mere 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, which diminishes its appeal among dividend investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, facing headwinds from disappointing COVID vaccine sales and several profitable drugs losing patent protection, particularly Ibrance and Eliquis, which raises concerns about its future growth prospects.
- R&D Resilience and Risks: Although Pfizer faced setbacks in GLP-1 drug development, it is actively acquiring more promising drug candidates and plans to conduct 20 major new drug studies in 2026, demonstrating its resilience in navigating industry challenges.
See More
Strong Dividends Drive Returns for Pfizer and JNJ Investments
- Dividend Growth: Johnson & Johnson (JNJ) has raised its quarterly dividend to $1.34 for the 64th consecutive time, resulting in an annual payout of $2,680, reflecting its AAA-rated financial stability and $19.7 billion in free cash flow, which bolsters investor confidence.
- Revenue Performance: JNJ's Innovative Medicine segment generated $15.426 billion in Q1 2026, an 11.2% year-over-year increase, primarily driven by strong sales of products like DARZALEX, further solidifying its market position.
- Pfizer's Dividend Strategy: Pfizer (PFE) offers a 6.8% dividend yield, and despite facing post-COVID sales declines, management prioritizes dividend payments and has stated no share buybacks are anticipated in 2026, ensuring stable returns for shareholders.
- Portfolio Income: The combined investment of 500 shares in these two companies generates $3,540 in annual passive income, with a blended yield of 2.79%, showcasing the appeal and flexibility of dividend stocks amid market fluctuations.
See More
Is It Possible to Retire on $500,000?
- Investment Return Requirements: To achieve a median U.S. household income of $88,510 from an initial investment of $500,000, an annual return of 17.7% is necessary, which is challenging but feasible with strategic investments.
- Social Security Impact: Including the average annual Social Security benefit of $26,148 reduces the required annual return to 12.5%, and for married couples receiving benefits, it drops to 7.2%, highlighting the critical role of Social Security in retirement planning.
- Ares Capital Advantages: As the largest publicly traded business development company, Ares Capital boasts a diversified portfolio worth $21.5 billion and offers a high dividend yield of 10.6%, having maintained stable or increasing dividends for 67 consecutive quarters, demonstrating strong profitability and resilience.
- Energy Transition Potential: Energy Transfer LP operates over 140,000 miles of pipelines, providing an attractive distribution yield of approximately 7.2%, with management projecting annual distribution growth of 3% to 5%, positioning the company strongly for growth amid energy transition trends.
See More
Ares Capital and Pfizer Offer High-Yield Stocks for Retirement
- Stable Dividends from Ares Capital: Ares Capital (NASDAQ: ARCC), the largest publicly traded business development company, offers a high dividend yield of 10.6% and has maintained stable or increasing dividends for 67 consecutive quarters, demonstrating resilience and profitability even during economic crises.
- Tailwinds from Energy Transition: Energy Transfer (NYSE: ET), a leading midstream energy company in North America with over 140,000 miles of pipelines, expects to increase its distribution by 3% to 5% annually and benefits from the rapid build-out of AI data centers, enhancing its market position.
- Pfizer's Long-Term Commitment: Pfizer (NYSE: PFE) boasts a forward dividend yield of 6.8% and has increased its dividend for 16 consecutive years; despite facing patent expirations, the company is investing in new product development and acquisitions to bolster revenue growth potential, expecting solid growth beyond 2028.
- Retirement Investment Advice: While Ares Capital, Energy Transfer, and Pfizer present good investment options for retirement, relying solely on these three stocks is unwise; investors are advised to create a diversified portfolio to mitigate risks and enhance return potential.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales growth of 56%, highlighting its strong performance in the weight-loss market.
- Dividend Yield Comparison: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at only 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, posing challenges in attracting income-focused investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, placing it at a competitive disadvantage.
- Future Outlook: Although Pfizer faces multiple challenges, it is actively developing new drugs and plans to conduct 20 major studies in 2026, demonstrating its ongoing efforts in drug development and potential for recovery.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Eli Lilly Sales Surge: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving a remarkable 56% overall sales growth, highlighting its strong position in the weight-loss market.
- Pfizer's Dividend Appeal: Pfizer offers a dividend yield of 6.6%, significantly higher than Eli Lilly's 0.6%, making it more attractive to income-focused investors despite facing challenges such as patent expirations.
- Challenges for Pfizer: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, raising concerns about its future growth.
- R&D Outlook: Despite short-term challenges, Pfizer is conducting 20 major studies on new drug candidates, indicating ongoing investment in drug development, which may enable it to regain growth momentum in the future.
See More
Eli Lilly vs Pfizer: Dividend Yield Comparison
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales gain of 56% for the company, highlighting its strong performance in the weight-loss market.
- Dividend Yield Discrepancy: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at a mere 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, which diminishes its appeal among dividend investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, facing headwinds from disappointing COVID vaccine sales and several profitable drugs losing patent protection, particularly Ibrance and Eliquis, which raises concerns about its future growth prospects.
- R&D Resilience and Risks: Although Pfizer faced setbacks in GLP-1 drug development, it is actively acquiring more promising drug candidates and plans to conduct 20 major new drug studies in 2026, demonstrating its resilience in navigating industry challenges.
See More
